Author:
Miyamoto Toshihiro, ,Nagafuji Koji,Fujisaki Tomoaki,Uchida Naoyuki,Matsue Kosei,Henzan Hideho,Ogawa Ryosuke,Takase Ken,Aoki Takatoshi,Hidaka Michihiro,Teshima Takanori,Taniguchi Shuichi,Akashi Koichi,Harada Mine
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Mrozek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012;30(36):4515–23.
2. Schlenk RF. Post-remission therapy for acute myeloid leukemia. Haematologica. 2014;99(11):1663–70.
3. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075–83.
4. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58(18):4173–9.
5. O’Donnel MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Bhatt V, et al. NCCN clinical practice guidelines in oncology. AML. NCCN guidelines version 3. 2017. https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf . Accessed 13 Dec 2017.